Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Grand View Research | PRODUCT CODE: 1679410

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1679410

Prostate Cancer Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Prostate Cancer Therapeutics Market Growth & Trends:

The global prostate cancer therapeutics market size is expected to reach USD 22.0 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.6% from 2025 to 2030. The growth of the market is attributed to the escalating prevalence of prostate cancer which in turn increases the demand for novel therapeutics. For instance, as per the ACS in 2022, prostate cancer is expected to have 268,490 new cases and lead to the death of 34,500 people worldwide. It affects roughly one out of every eight men at some point in their lives and is more common in older men.

A surge in government funding and increased public and private sector initiatives to enhance knowledge, and awareness about the availability of medicines amongst the public are projected to accelerate market growth. Furthermore, a rising preference for online drug purchasing over traditional methods, an increase in the number of internet users, and a rise in awareness regarding online pharmacies are expected to enhance the treatment adoption rate.

As per the American Cancer Society, in 2022, prostate cancer is the second leading cause of death in the male population of the U.S. Around one man in every 41 dies from prostate cancer. Although prostate cancer is a deadly disease, the mortality rate from the disease is low. The availability of a supportive regulatory landscape is expected to drive the adoption of novel products such as 177Lu-PSMA-617, which is precision medicine for patients that have not been cured with multiple rounds of treatment. The product received FDA approval in March 2022 for the treatment of mCRPC.

Targeted and biological therapy, chemotherapy, and hormonal therapy are some of the methods used to treat the condition. The high cost of targeted therapies and other immunotherapies is projected to act as a significant limitation on the global market. Low awareness of technological advancements in the therapeutic area in developing countries is expected to become a restrain for the market.

New trials are being conducted by institutes such as MRC Clinical Trials Unit at UCL. A June 2022, publication by the institute highlights secondary cancer tumor type of prostate cancer patients are benefited more from the use of chemotherapy such as docetaxel with an enhanced survival rate of 39%. These studies are creating a more effective way of providing a personalized medicine approach to prostate cancer patients so that they experience fewer side effects.

Prostate Cancer Therapeutics Market Report Highlights:

  • By drug class, the hormonal therapy segment held the largest share and is expected to be the fastest-growing segment due to the availability and efficient mechanism of action for treating the diseased condition completely
  • Xtandi drug is expected to grow at the fastest rate over the forecast period due to the high adoption of the drug and usage of the drug for longer periods of time
  • North America dominated the market in 2024 and is anticipated to be the fastest-growing region owing to an increase in the disease's prevalence, and a strong need for prostate cancer therapeutic products in the region
  • Key market players operating in the market are focusing on developing novel products to meet the demand and provide efficient treatment options
Show more
Product Code: GVR-1-68038-925-8

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Prostate Cancer Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis

Chapter 4. Prostate Cancer Therapeutics Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2024 & 2030
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 4.4. Hormonal Therapy
    • 4.4.1. Hormonal Therapy Market, 2018 - 2030 (USD Million)
  • 4.5. Chemotherapy
    • 4.5.1. Chemotherapy Market, 2018 - 2030 (USD Million)
  • 4.6. Immunotherapy
    • 4.6.1. Immunotherapy Market, 2018 - 2030 (USD Million)
  • 4.7. Targeted Therapy
    • 4.7.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Prostate Cancer Therapeutics Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2030
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 5.5. Drug Stores & Retail Pharmacies
    • 5.5.1. Drug Stores & Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 5.6. Online Pharmacies
    • 5.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 6. Prostate Cancer Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Prostate Cancer Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Prostate Cancer Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Norway
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Norway Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Denmark
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Denmark Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Sweden
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Sweden Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Prostate Cancer Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. South Korea Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. Australia Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Thailand Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Prostate Cancer Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA Prostate Cancer Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Johnson & Johnson Services, Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Astellas Pharma Inc.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Eli Lilly and Company
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Sanofi
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Ipsen Pharma
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Bayer AG
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. AstraZeneca
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Bausch Health Companies Inc.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Merck & Co., Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Pfizer Inc.
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives
Show more
Product Code: GVR-1-68038-925-8

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global prostate cancer therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 5 Global prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 North America prostate cancer therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 8 North America prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 US prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 US prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 Canada prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 12 Canada prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 13 Mexico prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 14 Mexico prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 15 Europe prostate cancer therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 17 Europe prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 18 UK prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 19 UK prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Germany prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 21 Germany prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 22 France prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 France prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 Italy prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 25 Italy prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 26 Spain prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 27 Spain prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 Norway prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Norway prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30 Denmark prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 31 Denmark prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 32 Sweden prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 33 Sweden prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific prostate cancer therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Japan prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 38 Japan prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39 China prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 40 China prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 41 India prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 42 India prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 43 Australia prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 44 Australia prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 South Korea prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 46 South Korea prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 47 Thailand prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 48 Thailand prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49 Latin America prostate cancer therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 50 Latin America prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 51 Latin America prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 Brazil prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 53 Brazil prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 54 Argentina prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 55 Argentina prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa prostate cancer therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 59 South Africa prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 60 South Africa prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 63 UAE prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 64 UAE prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 65 Kuwait prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 66 Kuwait prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Prostate Cancer Therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Drug class and distribution channel outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Prostate cancer therapeutics market dynamics
  • Fig. 12 Prostate cancer therapeutics market: Porter's five forces analysis
  • Fig. 13 Prostate cancer therapeutics market: PESTLE analysis
  • Fig. 14 Prostate cancer therapeutics market: Drug class segment dashboard
  • Fig. 15 Prostate cancer therapeutics market: Drug class market share analysis, 2024 & 2030
  • Fig. 16 Hormonal therapy market, 2018 - 2030 (USD Million)
  • Fig. 17 Chemotherapy market, 2018 - 2030 (USD Million)
  • Fig. 18 Immunotherapy market, 2018 - 2030 (USD Million)
  • Fig. 19 Targeted therapy market, 2018 - 2030 (USD Million)
  • Fig. 20 Others market, 2018 - 2030 (USD Million)
  • Fig. 21 Prostate cancer therapeutics market: Distribution channel segment dashboard
  • Fig. 22 Prostate cancer therapeutics market: Distribution channel market share analysis, 2024 & 2030
  • Fig. 23 Hospital pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 24 Drug stores & retail pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 25 Online pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 26 Prostate cancer therapeutics market revenue, by region
  • Fig. 27 Regional marketplace: Key takeaways
  • Fig. 28 Regional marketplace: Key takeaways
  • Fig. 29 North America prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. country dynamics
  • Fig. 31 U.S. prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 32 Canada country dynamics
  • Fig. 33 Canada prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 34 Mexico country dynamics
  • Fig. 35 Mexico prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 36 Europe prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 37 UK country dynamics
  • Fig. 38 UK prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 39 Germany country dynamics
  • Fig. 40 Germany prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 41 France country dynamics
  • Fig. 42 France prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 43 Italy country dynamics
  • Fig. 44 Italy prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 45 Spain country dynamics
  • Fig. 46 Spain prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 47 Norway country dynamics
  • Fig. 48 Norway prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 49 Sweden country dynamics
  • Fig. 50 Sweden prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 51 Denmark country dynamics
  • Fig. 52 Denmark prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 53 Asia Pacific prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 54 Japan country dynamics
  • Fig. 55 Japan prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 56 China country dynamics
  • Fig. 57 China prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 58 India country dynamics
  • Fig. 59 India prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 60 Australia country dynamics
  • Fig. 61 Australia prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 62 South Korea country dynamics
  • Fig. 63 South Korea prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 64 Thailand country dynamics
  • Fig. 65 Thailand prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 66 Latin America prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 67 Brazil country dynamics
  • Fig. 68 Brazil prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 69 Argentina country dynamics
  • Fig. 70 Argentina prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 71 MEA prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 72 South Africa country dynamics
  • Fig. 73 South Africa prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 74 Saudi Arabia country dynamics
  • Fig. 75 Saudi Arabia prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 76 UAE country dynamics
  • Fig. 77 UAE prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 78 Kuwait country dynamics
  • Fig. 79 Kuwait prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 80 Company categorization
  • Fig. 81 Company market position analysis
  • Fig. 82 Strategic framework
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!